BNT-113
- Generic Name
- BNT-113
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Phase 2
Recruiting
- Conditions
- Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 350
- Registration Number
- NCT04534205
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸UCLA Cancer Care, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
HARE-40: HPV Anti-CD40 RNA vaccinE
Phase 1
Completed
- Conditions
- Human Papilloma Virus Related CarcinomaHead and Neck NeoplasmCervical NeoplasmUnknown Primary TumorsPenile Neoplasms Malignant
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Southampton
- Target Recruit Count
- 32
- Registration Number
- NCT03418480
- Locations
- 🇬🇧
Univeristy Hospitals Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath